Non-oncologic patients with Chronic Fatigue Syndrome have increased levels of pro-inflammatory cytokines such as IL1 beta, IL 1 receptor antagonist and TNF-alpha [20,21], and fatigue is a major side effect of cancer patients receiving interleukins, TNF-alpha and interferon [22-24]. This evidence concerns the gene TNF and myalgic encephalomeyelitis/chronic fatigue syndrome.